29 reports

CARDIOVASCULAR DISEASES ARE A GROUP OF DISORDERS OF THE HEART AND BLOOD VESSELS AND INCLUDE CORONARY HEART DISEASE, CEREBROVASCULAR DISEASE, PERIPHERAL ARTERIAL DISEASE, RHEUMATIC HEART DISEASE, AND CONGENITAL HEART

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

CARDIOVASCULAR DISEASES ARE A GROUP OF DISORDERS OF THE HEART AND BLOOD VESSELS AND INCLUDE CORONARY HEART DISEASE, CEREBROVASCULAR DISEASE, PERIPHERAL ARTERIAL DISEASE, RHEUMATIC HEART DISEASE, AND CONGENITAL HEART

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

AEs include, but are not limited to, the development of osteoporosis, osteonecrosis, cataracts, hyperglycemia, coronary heart disease, cognitive impairment, weight gain, and increased susceptibility to infections.

  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • United States
  • World

THESE INCLUDE, BUT ARE NOT LIMITED TO, THE DEVELOPMENT OF OSTEOPOROSIS, OSTEONECROSIS, CATARACTS, HYPERGLYCEMIA, CORONARY HEART DISEASE, COGNITIVE IMPAIRMENT, WEIGHT GAIN, AND INCREASED SUSCEPTIBILITY TO INFECTIONS.

  • Targeted Therapy
  • World
  • Market Size
  • AstraZeneca PLC
  • Merck & Co., Inc.

(SHARP) GDCT## NCT##, U##-##-##; SKNMC& GH- HS/ ##/ 2016; ISRCTN##; CTRI/ 2018/ ##/ ##; CTRI/ 2017/ ##/ ##; SKNMC/ Ethics/ Corr/ 2016/ ## Cardiovascular Atherosclerosis, Cerebrovascular Disease,

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Product Initiative

(SHARP) GDCT## NCT##, U##-##-##; SKNMC& GH-HS/ ##/ 2016; ISRCTN##; CTRI/ 2018/ ##/ ## Cardiovascular Atherosclerosis, Cerebrovascular Disease, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Deep Vei

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Targeted Therapy
  • World

MACE is an umbrella term that includes heart attack, ischemic stroke, death from coronary heart disease and unstable angina requiring hospitalization.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Clinical Trial
  • Drug Development
  • Targeted Therapy
  • World
  • Synergenics, LLC

Coronary Perfusion Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease GDCT## NCT##, Cardiovascular Endothelial Dysfunction, Systemic Lupus Erythematosus Completed Phase IV Interventional quinapril University Health Network

  • Clinical Trial
  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • World

A Three-Year Randomised Double-Blind Placebo-Controlled International Multicentre Study Effects of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction GDCT## NCT##, CL##-##-##; 2004-001959-##; EudraCT-2004-001959-## Cardi

  • Cardiology
  • Cardiovascular Disease
  • Clinical Trial
  • Targeted Therapy
  • World

(Woest ##) GDCT## NCT##, R& D/ Z##. ##/ WOEST##; WOEST##-##; V. ##/ W##. ## Cardiovascular Acute Coronary Syndrome, Atrial Fibrillation, Bleeding And Clotting Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease),

  • Chronic Disease
  • Clinical Trial
  • Heart Attack
  • Targeted Therapy
  • World

Paul Heart Clinic Amylin Pharmaceuticals, Inc.

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Product Initiative

And a a Combination of Folic Acid and B-group Vitamins Therapy on the Incidence of Contrast-induced Nephropathy in High Homocysteine Patients with Stable Coronary Artery Disease The Effect of Hyperhomocystinemia on the Morbidity of Contrast-induced Nephropathy in Patients with

  • Clinical Trial
  • Drug Development
  • Targeted Therapy
  • World
  • Product Initiative

Acute coronary syndrome, or ACS, occurs when blood flow to the heart is suddenly blocked.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Targeted Therapy
  • World

Lipitor is used to treat high cholesterol, lower the risk of stroke, heart attack, or other heart complications in people with Type ## diabetes, coronary heart disease, or other risk factors.

  • Healthcare
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

AND FOR THE PREVENTION OF CORONARY HEART DISEASE RISK EVENTS (IN THE U. S.

  • Blood Disease
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

AND FOR THE PREVENTION OF CORONARY HEART DISEASE RISK EVENTS (IN THE U. S.

  • Blood Disease
  • Cancer
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • Transplantation
  • Novartis AG

High-dose Pitavastatin on In-stent Restenosis, Endothelial Function, Circulating microRNAs, and Cardiovascular Events in Patients with Coronary Artery Disease Requiring Stent Implantation: OCT and NIRS Comparison Effect of Low-dose vs.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Targeted Therapy
  • World

Paul Heart Clinic Amylin Pharmaceuticals, Inc.

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Novartis AG

The poster showed favorable effects of the apoA-I inducer RVX-## on coronary disease progression and MACE.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Company
  • Product Initiative

OXA. ## Cardiovascular Atherosclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Endothelial Dysfunction, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Type ## Diabetes (Adiponectin (## Kda Adipocyte Co

  • Cardiology
  • Clinical Trial
  • Pharmaceutical
  • Targeted Therapy
  • World

ITS PRODUCT PORTFOLIO COMPRISES OF CVBT-##B IN PHASE-III CLINICAL TRIALS STAGE FOR DERMAL WOUND HEALING IN DIABETIC PATIENTS; CVBT-##H IN PHASE-II CLINICAL TRIALS STAGE FOR THE TREATMENT OF SEVERE CORONARY HEART DISEASE; AND CVBT-##C RECEIVED APPROVAL FOR PHASE-I CLINIC

  • Renal Cancer
  • Targeted Therapy
  • United States
  • Company
  • Product Initiative

IT IS IN PHASE III STAGE OF DEVELOPMENT FOR HYPERCHOLESTEROLEMIA AND FOR PREVENTION OF CORONARY HEART DISEASE RISK EVENTS IN SOUTH KOREA AND TAIWAN.

  • Lipid Modifying Drug
  • Targeted Therapy
  • United States
  • Company
  • Product Initiative

It is in Phase III stage of development for hypercholesterolemia and for prevention of coronary heart disease risk events in South Korea and Taiwan.

  • Pharmaceutical
  • Targeted Therapy
  • United States
  • Company Operations
  • Regeneron Pharmaceuticals, Inc.

Its product portfolio comprises of CVBT- ##B in Phase-III clinical trials stage for dermal wound healing in diabetic patients; CVBT-##H in Phase-II clinical trials stage for the treatment of severe coronary heart disease; and CVBT-##C received approval for Phase-I clini

  • Hospital
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Eisai Co., Ltd.
  • DISCONTINUED PIPELINE PRODUCT PROFILES

RG## was under development for the treatment of coronary heart disease, hyperlipidemia and metabolic disease.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Company Operations
  • Genentech, Inc.

Mechanism of Action Pfizer Inc. is developing PF-## for the treatment of coronary heart disease.

  • Monoclonal Antibody
  • Pathology
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

JTT-## (dalcetrapib, RG##, RO##) was under development for the treatment of dyslipidemia, artherosclerosis, risk reduction in coronary heart disease/ cardiovascular disease, cardiovascular risk reduction post acute coronary syndrome and hyperlipidemia.

  • Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • United States